<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732429</url>
  </required_header>
  <id_info>
    <org_study_id>HST20-CL01</org_study_id>
    <nct_id>NCT04732429</nct_id>
  </id_info>
  <brief_title>Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia</brief_title>
  <acronym>HERO</acronym>
  <official_title>A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HemoShear Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HemoShear Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional study to assess the safety, PK, and efficacy of HST5040 in 12&#xD;
      subjects - 6 with Methylmalonic Acidemia (MMA) and 6 with Propionic Acidemia (PA). The study&#xD;
      consists of 3 parts:&#xD;
&#xD;
        -  Part A: Open-label, within-subject, dose escalation study in PA and MMA subjects ≥ 2&#xD;
           years old to identify a safe and pharmacologically active (optimal) dose of HST5040 for&#xD;
           use in Part B. Subjects will continue in a Part A open-label extension until all&#xD;
           subjects complete Part A and the optimal dose of HST5040 is identified for use in Part&#xD;
           B.&#xD;
&#xD;
        -  Part B: 6-month, randomized, double-blind, placebo-controlled, 2-period crossover in the&#xD;
           same subjects from Part A to evaluate safety and efficacy of the optimal dose of HST5040&#xD;
           in addition to standard of care (SoC).&#xD;
&#xD;
        -  Part C: open-label long-term extension study in PA and MMA subjects ≥ 2 years old (N =&#xD;
           approximately 12, 6 each) to evaluate the long-term safety and efficacy of the optimal&#xD;
           dose of HST5040.&#xD;
&#xD;
      This study will determine whether HST5040 can improve levels of disease-associated toxins&#xD;
      that accumulate in patients with PA and MMA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma 2-methylcitric acid (MCA) levels</measure>
    <time_frame>6 months</time_frame>
    <description>nmol/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma propionyl-carnitine (3)</measure>
    <time_frame>6 months</time_frame>
    <description>µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C3 to acetyl-carnitine ratio (C3:C2)</measure>
    <time_frame>6 months</time_frame>
    <description>µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 3-OH propionate</measure>
    <time_frame>6 months</time_frame>
    <description>g/mol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Methylmalonic acid (in MMA subjects)</measure>
    <time_frame>6 months</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NH3</measure>
    <time_frame>6 months</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anion Gap</measure>
    <time_frame>6 months</time_frame>
    <description>mEq/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters - Cmax</measure>
    <time_frame>6 months</time_frame>
    <description>Maximum concentration (Cmax) after administration of HST5040</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters - Tmax</measure>
    <time_frame>6 months</time_frame>
    <description>Time of maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters - AUC</measure>
    <time_frame>6 months</time_frame>
    <description>Area under the concentration time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Intake</measure>
    <time_frame>6 months</time_frame>
    <description>Food diary - change from baseline to end of each dose level interval in oral intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Metabolic Decompensations</measure>
    <time_frame>6 months</time_frame>
    <description>Change in the total number of metabolic decompensation events requiring an emergency room (ER) visit of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MetabQoL 1.0 - Health Related Quality of Life (HRQOL)</measure>
    <time_frame>6 months</time_frame>
    <description>Score 0-100 Scale. Higher Score indicates better HRQOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL 1.0 Family Impact Score - Health Related Quality of Life (HRQOL)</measure>
    <time_frame>6 months</time_frame>
    <description>Score 0-100 Scale. Higher Score indicates better HRQOL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Methylmalonic Acidemia</condition>
  <condition>Propionic Acidemia</condition>
  <arm_group>
    <arm_group_label>Active Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B is the 6-month, randomized, double-blind (Subject/Investigator/Sponsor), placebo-controlled, 2-period crossover study consisting of 2 intervention periods of 12 weeks each to evaluate the safety and efficacy of the optimal dose of HST5040 in PA and MMA subjects ≥ 2 years old (N = minimum 12) in addition to SoC determined in Part A (within-subject dose escalation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in addition to standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HST5040</intervention_name>
    <description>Liquid solution</description>
    <arm_group_label>Active Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Liquid solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of symptomatic PA or MMA (Mutase)&#xD;
&#xD;
          -  Ages ≥ 2 years old.&#xD;
&#xD;
          -  Inadequate metabolic control while receiving standard of care (SoC) within the past 4&#xD;
             years.&#xD;
&#xD;
          -  Plasma MCA concentration &gt; 3x upper limit of normal of the reference range at&#xD;
             screening.&#xD;
&#xD;
          -  Stable supplementation dose of carnitine for at least 1 week prior to the entry in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moderate-to-severely impaired cardiac function with LVEF &lt; 45% by ECHO.&#xD;
&#xD;
          -  Clinically significant arrhythmia by Holter monitor.&#xD;
&#xD;
          -  QTcF &gt; 450 msec&#xD;
&#xD;
          -  Moderate to severe chronic kidney disease with estimated glomerular filtration rate&#xD;
             (eGFR) &lt; 60 mL/min/1.73m2.&#xD;
&#xD;
          -  Exposure to any investigational therapy, apart for a COVID-19 vaccine, within the past&#xD;
             6 months prior to study entry.&#xD;
&#xD;
          -  Exposure to gene therapy for PA or MMA at any time prior to study entry.&#xD;
&#xD;
          -  History of organ transplantation (Part A and B only)&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to any of the components of&#xD;
             HST5040.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald F Cox</last_name>
    <role>Study Chair</role>
    <affiliation>HemoShear Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mavis Y Waller</last_name>
    <phone>833-975-3559</phone>
    <email>waller@hemoshear.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allison J Armstrong</last_name>
    <phone>833-975-3559</phone>
    <email>Armstrong@hemoshear.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clara Garrison</last_name>
      <phone>858-966-8247</phone>
      <email>cgarrison@rchsd.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Spencer-Manzon, MD</last_name>
      <phone>203-785-2660</phone>
      <email>michele.spencer-manzon@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesly Atley</last_name>
      <email>LATLEY@childrensnational.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Maegawa, MD, PhD</last_name>
      <phone>352-294-5559</phone>
      <email>gmaegawa@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Anastasoaie</last_name>
      <phone>617-355-7347</phone>
      <email>Vera.Anastasoaie@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Elsbecker</last_name>
      <phone>612-626-5275</phone>
      <email>selsbeck10@umphysicians.umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kemi Lewis</last_name>
      <phone>816-302-8419</phone>
      <email>kjlewis@cmh.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Tumblin</last_name>
      <phone>412-692-5969</phone>
      <email>mark.tumblin2@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LeeAnna Melton</last_name>
      <phone>615-343-6761</phone>
      <email>leeanna.melton@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenzie Fait</last_name>
      <phone>801-585-7160</phone>
      <email>kenzie.fait@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methylmalonic Acidemia</keyword>
  <keyword>Propionic Acidemia</keyword>
  <keyword>Organic Acidemia</keyword>
  <keyword>Inborn errors of metabolism</keyword>
  <keyword>PCCA</keyword>
  <keyword>PCCB</keyword>
  <keyword>Propionyl-coenzyme A carboxylase</keyword>
  <keyword>MMUT</keyword>
  <keyword>Methylmalonyl-CoA mutase</keyword>
  <keyword>Metabolic disease</keyword>
  <keyword>Genetic disease</keyword>
  <keyword>HemoShear</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Propionic Acidemia</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

